VCNX (Vaccinex) Accounts Receivable: $0.84 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCNX Vaccinex Inc VCNX
50 GF Score
Price $1.18
View Full Analysis

What is Vaccinex Accounts Receivable?

Vaccinex VCNX 50 Accounts Receivable is $0.84 Mil as of Dec. 2024. GuruFocus rates VCNX with a GF Score™ of 50/100.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Vaccinex's accounts receivables for the quarter that ended in Dec. 2024 was $0.84 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Vaccinex's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 359.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Vaccinex's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $-1.87.


Vaccinex Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Vaccinex's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.838/0.213*91
=359.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Vaccinex's accounts receivable are only considered to be worth 75% of book value:

Vaccinex's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1.107+0.75 * 0.838+0.5 * 0-5.084
-1.665-0)/2.677
=-1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Vaccinex Accounts Receivable Related Terms


Vaccinex Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Vaccinex's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaccinex Accounts Receivable Chart

Vaccinex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only 0.16 0.00 0.18 0.96 0.84

Vaccinex Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 2.78 1.05 0.99 0.84
VCNX
50GF Score
Vaccinex Inc VCNX
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaccinex Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of $0.84 Mil mean?
Vaccinex (VCNX) has a Accounts Receivable of $0.84 Mil as of Dec. 2024. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Vaccinex and its competitors.
Is Vaccinex's Accounts Receivable too high?
Vaccinex's current Accounts Receivable is $0.84 Mil. Overall, Vaccinex has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Vaccinex's Accounts Receivable compare to SXTP and PHGE?
Vaccinex's Accounts Receivable of $0.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Vaccinex and its competitors. Vaccinex's current Accounts Receivable is $0.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaccinex stock overvalued right now?
Vaccinex (VCNX) has a current Accounts Receivable of $0.84 Mil. The current Accounts Receivable is $0.84 Mil. Vaccinex's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Vaccinex (VCNX), the current Accounts Receivable is $0.84 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vaccinex Business Description

Address 1895 Mount Hope Avenue, Rochester, NY, USA, 14620
Vaccinex Inc is a clinical stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company operates and manages its business as one operating and reportable segment, which is the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. The firm has also developed a proprietary drug discovery platform, ActivMAb.
50GF Score

Get the complete analysis for VCNX

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price